Gilead's lenacapavir has shown unprecedented results in recent trials, with a 100% effectiveness rate among young women, prompting new hope in HIV prevention strategies.
Recent trials demonstrated that lenacapavir reduced HIV infections by 96% among gay men and trans individuals, outweighing the effectiveness of daily PrEP pills.
Collection
[
|
...
]